InvaGen. FDP..90 fit P(Do47. Citizen petitian
|
|
- Janice Henderson
- 6 years ago
- Views:
Transcription
1 InvaGen Pharmaceuticals, I nt. InvaGen Pharmaceuticals, Inc. Te1: Fax: : Division of Dockets Management Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD January 14, J 416. ooloo Cg '61; A Citizen petitian Re: Citizen Petition to InvaGen's Meclizine Hydrochloride Chewable Tablets, 25 mg ANDA # Dear Sir/Madam, I have herewith enclosed the Citizen Petition document, in reference to the telephonic conversation with OGD on 12/06/2010, to file the citizen petition for further review of InvaGen's Meclizine Hydrochloride chewable tablets, 25 mg ANDA # with the following reason. "InvaGen submitted the ANDA # on 11/19/09 with Pfizer's Antivert (meclizine HC1) Chewable Tablets, 25 mg as RLD and was accepted as an ANDA as was the case at the time of ANDA submission, Pfizer's Antivert Chewable Tablets,25 mg held RLD status though Antivert Chewable Tablets 25 mg were not available in the market. Currently the RLD status in orange book for Pfizer 's Antivert Chewable Tablets 25 mg is revised as "discontinued". Accordingly InvaGen should file the citizen petition to confirm the Pfizer's Antivert chewable tablets 25 mg was not discontinued for safety and efficacy reasons and also to re list the InvaGen's drug product Meclizine Hydrochloride chewable tablets, 25 mg as RLD." In reference to the above, InvaGen is filing the citizen petition document in accordance with section 505(j) (2) (C) of the Federal Food, Drug and Cosmetic Act and 21 CFR and 21 CFR and firm is committed to assist with any issues identified. FDP..90 fit P(Do47 ce
2 InvaGen P ha rmaceuticals, InvaGen Pharmaceuticals, Inc. Te1: Fax: If there are any questions or comments, please do not hesitate to contact me via telephone at (631) or via facsimile at (631) Sincerely, Sudhakar R. Vidiyala, Ph.D.
3 InvaGen jfl JAN 18 NO :14 InvaGen Inc. January 14, Division of Dockets Management Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD CITIZEN PETITION The undersigned, submits this petition under section 505(j) (2) (C) of the Federal Food, Drug and Cosmetic Act and 21 CFR and 21 CFR requesting the Commissioner of Food and Drugs to make a determination that the Pfizer's Antivert chewable tablets 25 mg, containing Meclizine Hydrochloride 25 mg per tablet was not discontinued for safety and efficacy reasons and is suitable for the submission of an Abbreviated New Drug Application (ANDA) and also to re list the InvaGen's drug product Meclizine Hydrochloride chewable tablets, 25 mg as RLD. A. Action Requested InvaGen requests the Commissioner of the Food and Drug Administration to make a determination that the discontinued formulation Pfizer's Antivert Chewable Tablets 25 mg was not discontinued for safety and efficacy reasons. The petitioner believes that the Pfizer's Antivert Chewable Tablets, 25 mg was not withdrawn for the reasons of safety and efficacy. The continued presence of Antivert Tablets, 25 mg (current RLD held by Pfizer for Antivert Oral Tablets) on the market is a clear indication that the discontinued product(antivert Chewable Tablets, 25 mg) remains safe and effective since both are identical with respect to active ingredient, strength and route of administration except the dosage form. The petitioner therefore requests that its Meclizine Hydrochloride Chewable Tablets, 25 mg ANDA is eligible for approval upon completion of the review process, though the currently Pfizer's Antivert Chewable Tablets, 25 mg are having discontinued status in Orange book.
4 InvaGen Inc!nyeGen Inc. This petition therefore requests the Commissioner of the Food and Drug Administration to make a determination that : 1. The Pfizer's Antivert chewable tablets 25 mg, containing Meclizine Hydrochloride 25 mg per tablet was not discontinued for safety and efficacy reasons. 2. The Drug Product Meclizine Hydrochloride chewable tablets, 25 mg is suitable for consideration in an Abbreviated New Drug Application; and 3. to re list the InvaGen's drug product Meclizine Hydrochloride chewable tablets, 25 mg as RLD (hereinafter referred to as "proposed RLD product") in place of Pfizer's discontinued RLD Antivert Chewable Tablets, 25 mg, since there is no RLD in the marketing status and the InvaGen's Drug product will be the first available approved prescription product for chewable tablets in the market, up on approval of its ANDA # B. Statement of Grounds The active ingredient in both Antivert Tablets 25 mg (oral ) and Antivert chewable Tablets 25 mg, i.e., Meclizine is an antihistamine which shows marked protective activity against nebulized histamine and lethal doses of intravenously injected histamine in guinea pigs. It has a marked effect in blocking the vasodepressor response to histamine, but only a slight blocking action against acetylcholine. Its activity is relatively weak in inhibiting the spasmogenic action of histamine on isolated guinea pig ileum. The Pfizer's Antivert was approved for both Oral tablets and chewable on February 14, 1957 under NDA # The InvaGen's proposed RLD product Meclizine Hydrochloride chewable tablets, 25 mg has been developed for chewable tablet.
5 InvaGen Inc!nyeGen Inc. Petitioner submitted the ANDA # with Pfizer's Antivert Chewable Tablets, 25 mg as RLD (as was the case at the time of ANDA submission, Pfizer's Antivert Chewable Tablets,25 mg held RLD status though Antivert Chewable Tablets 25 mg were not available in the market ) is valid and approvable subject to meeting the Agency's requirements for filing an ANDA.(Please refer Attachment -1 for the copies of the relevant pages of November,09 Orange Book). Later orange book was revised the RLD status for Pfizer's Antivert Chewable Tablets 25 mg as "discontinued" (Please refer Attachment -2 for the copies of the relevant pages from current Orange Book discontinued products) and accordingly FDA requested InvaGen to file the citizen petition to confirm The Pfizer's Antiverte chewable tablets 25 mg were not discontinued for safety and efficacy reasons and also to re list the InvaGen's drug product Meclizine Hydrochloride chewable tablets, 25 mg as RLD for further continue the review process of its ANDA # The petitioner particularly requests the FDA to make a determination that InvaGen's Meclizine Hydrochloride Chewable Tablets,25 mg referring to the originally approved RLD Antivert Chewable Tablets, 25 mg (now discontinued) would not render the product less safe or effective based on the following facts. B.1. Referencing discontinued RLD and Regulations : The Orange Book contains a list of all drug products approved by the Food and Drug Administration (FDA) which are eligible for submissions as ANDAs. The current date of the electronic Orange Book lists Antivert Chewable Tablets,25 mg, under the "Discontinued Drug Products section". It is known from the 21 U.S.0 Section 355 (j) (6) Code of Federal Regulations that when an ANDA makes a reference to a discontinued label of a drug, FDA may still approve the ANDA upon determination that the formulation was not withdrawn for reasons of safety or effectiveness.
6 InvaGen Inc InvaGen inc. The petitioner is not aware of any documentation which establish that the Antivert chewable tablets 25 mg was discontinued for safety or efficacy reasons. In FDA's "Additions/Deletions for prescription and OTC Drug products list", Antivert Chewable Tablets 25 mg has been marked with symbol "s", which indicates "drugs that have been discontinued from marketing or that have has their approvals withdrawn for other than safety or efficacy reasons. (Please refer attachment-3 for FDA's "Additions/Deletions for prescription and OTC Drug products listed January-2010, 30 th edition). In the Labeling comments dated, November 30, 2010 on InvaGen's Meclizine Hydrochloride Chewable Tablets, 25 mg ANDA #200791, OGD recommended to omit the text related to Vertigo in dosage and administration and other label contests, though the Antivert labeling used as reference listed label for InvaGen's Meclizine Hydrochloride Chewable Tablets, 25 mg ANDA # It is known from 21 C.F.R (a)(8)(iv), FDA is authorized to approve an ANDA that omits in its labeling an indication or other aspects for the listed drug. (Please refer attachment-4 for labeling copies of both brand Antivert labeling and InvaGen's Meclizine Hydrochloride Chewable Tablets labeling along the details of reasons for differences between brand and InvaGen's labeling) B.2. Conclusion: For all reasons stated above in this statement ground, the petitioner seeks FDA to make a determination that the discontinued formulation of Antivert chewable tablets 25 mg was not withdrawn by Pfizer for reasons of safety or effectiveness and that the use of that labeling, product would not render the InvaGen's Meclizine Hydrochloride Chewable Tablets, 25 mg less safe or effective and would be therapeutically equivalent to the currently marketed Pfizer's Antivert oral tablets 25 mg and discontinued Antivert Chewable Tablets, 25 mg. Accordingly, this petition seeks a determination that the InvaGen's drug product Meclizine Hydrochloride Chewable Tablets, 25 mg is suitable for submission as an Abbreviated New Drug Application (ANDA) and also to list as RLD product upon approval of InvaGen's ANDA #
7 InvaGen Inc InvaGen Inc. C. Environmental Impact: This petition is entitled to a categorical exclusion under 21 CFR and D. Economic Report: The petitioner agrees to provide an economic analysis if requested by the agency. E. Certification The undersigned certifies, that, to the best knowledge and belief of the undersigned, this petition includes all information and views on which the petition relies, and that it includes representative data and information known to the petitioner, which is unfavorable to the petitioner. Respectfully Submitted, Sudhakar.R. Vidiyala, Ph.D InvaGen Pharmaceuticals, Inc., Hauppauge, NY Attachments: 1. Copies of the relevant pages of November,09 Orange Book 2. Copies of the relevant pages from current Orange Book discontinued products. 3. FDA's "Additions/Deletions for prescription and OTC Drug products listed January-2010, 30 th edition. 4. Labeling copies of both brand Antivert and InvaGen's Meclizine Hydrochloride Chewable Tablets labeling along the comparison and reasons for differences between brand and InvaGen's labeling.
8 FedEx Ship Manager - Print Your Label(s) Page 1 of 1 From: Origin ID: WLMA (831) Dr. LU.S. Raju Hetero USA Inc nue Hauppauge, NY Fect&z. ExPress SHIP TO: (631) BILL SENDER Division of Dockets Management Food and Drug Administration 5630 FISHERS LN RM 1061 DEPARTMENT OF HEALTH AND HUMAN S ROCKVILLE, MD Ship Date: 14JAN11 ActWgt. 1.0 LB CAD: /INET3090 Delivery Address Bar Code Aconsi un Ref # Invoice # PO # Dep # TRK# MON 17 JAN A2 STANDARD OVERN I GHT SA OBTA MD-US I AD OAG I0 After printing this label 1. Use the 'Prinf button on this page to print your label to your laser or inkjet printer. 2. Fold the printed page along the horizontal line. 3. Place label in shipping pouch and affix it to your shipment so that the barcode portion of the label can be read and scanned Warning: Use only the printed original label for shipping. Using a photocopy of this label for shipping purposes is fraudulent and could result in additional billing charges, along with the cancellation of your FedEx account number. Use of this system constitutes your agreement to the service conditions in the current FedEx Service Guide, available on fedex.com.fedex will not be resportaible for any claim in excess of $100 per package, whether the result of loss, damage, delay, non-delivery,misdelivery,or misinformation, unless you declare a higher value, pay an additional charge, document your actual loss and file a timely claim.limitations found in the current FedEx Service Guide apply. Your right to recover from FedEx for any loss, including intrinsic valueof the package, loss of sales, income interest, profit, attorney's fees, costs, and other forms of damage whether direct, incidental,consequential, or special is limited to the greater of $100 or the authorized declared value. Recoveey cannot exceed actual documented loss.maximum for items of extraordinary value Is $500, e.g. jewelry, precious metals, negotiable instruments and other items listed in our ServiceGuide. Written claims must be filed within stnct time limits, see current FedEx Service Guide. Siobal Home I Small Business Center I Service Guide I About FedE> I Investor elations fedex corn Terms of Use I Security & Privacy Site Map l This site is protected by copyright and trademark laws under US and International law. All rights reserved FedEx 1/14/2011
FEB 28 A 9 :09
InvaGen Pharmaceutic als. Inc. InvaGen Pharmaceuticals, Inc. Te1:631-231-3233 Fax:631-231-4248 4 2 3 7 11 FEB 28 A 9 :09 Division of Dockets Management Food and Drug Administration Department of Health
More informationLACHMAN CONSULTANT SERVICES, INC STEWART AVENUE, WESTBURY, NY (516) " FAX (516) $,7,1 OVERNIGHT COURIER 11/16/09
LACHMAN CONSULTANT SERVICES, INC. CONSULTANTS TO THE PHARMACEUTICAL AND ALLIED INDUSTRIES 1600 STEWART AVENUE, WESTBURY, NY 11590 (516) 222-6222 " FAX (516) 683-18$,7,1 November 16, 2009 OVERNIGHT COURIER
More informationTHE WEINBERG GROUP VIA FEDEX. October l, 2009
.. 0 THE WEINBERG GROUP VIA FEDEX October l, 2009 Division of Dockets Management Food and Drug Administration (HFA-305) Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD
More informationF DA 'ac/0 --tii -oas SIEMENS. Sincerely, March 5, 2010
SIEMENS March 5, 2010 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re : Docket No. FDA-2010-N-0054. Strengthening the Center for
More informationANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015
DEPARTMENT OF HEALTH & HUMAN SERVICES Silver Spring, MD 20993 ANDA 060851 Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY 10970 Docket No. FDA-2011-P-0081
More informationNAVINTA LLC FEB loa II: 2 2. February 9, 2011
February 9, 2011 NAVINTA LLC 2011 FEB loa II: 2 2 Fax: 609883 1137 Ms. Michelle Bigesby, Division ofdocuments Management, Food and Drug Administration, Department ofhealth and Human Services; 5630 Fishers
More informationGuidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry DRAFT GUIDANCE This guidance
More informationNAVINTA LLC Fax:
AVITA LLC Fax: 609 883 1137! 2011 FEB - 8 A 10: 2q February 7, 2011 VIA OVERIGHT DELIVERY Division of Documents Management Food and Drug Administration Department of Health and Human Services 5630 Fishers
More informationUNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION
UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION Citizen Petition to: Margaret A. Hamburg, M.D, Commissioner of Food and Drugs Docket No. For Review of Standard of Identity
More informationOCT 1 7 A10 51
'. ' October 11, 2013 Division of Dockets Management Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville, MD 20852 4 6 6 4 13 OCT 1 7 A10 51 CITIZEN
More informationWithdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for
This document is scheduled to be published in the Federal Register on 12/14/2018 and available online at https://federalregister.gov/d/2018-27098, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationTeva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044
DEPARTMENT OF HEALTH & HUMAN SERVICES ANDA 090783 Food and Drug Administration Silver Spring, MD 20993 Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs
More informationHighly Concentrated Caffeine in Dietary Supplements; Guidance for Industry; Availability
This document is scheduled to be published in the Federal Register on 04/16/2018 and available online at https://federalregister.gov/d/2018-07836, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationI. BACKGROUND. Docket No. FDA-2009-P Dear Dr. Aikman:
DEPARTMENT OF HEALTH &. HUMAN SERVICES Food and Drug Administration Rockville MD 20857 Mark S. Aikman, Pharm.D. Vice President, Regulatory Affairs and Quality Assurance Osmotica Pharmaceutical Corp. 1205
More informationANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry
ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationOffice of Generic Drugs. April 14, 2010
Considerations for PET ANDAs Office of Generic Drugs April 14, 2010 1 Agenda Office of Generic Drugs: background information RLDs and Suitability Petitions Submission requirements for an ANDA Approval
More informationSUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated
This document is scheduled to be published in the Federal Register on 11/22/2017 and available online at https://federalregister.gov/d/2017-25245, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville, MD 20857 TEVA Pharmaceuticals LTD Attention: J. Michael Nicholas, Ph.D. Senior Director, U. S. Regulatory
More informationrj.;!i U.S. FOOD & DRUG - ADMIN ISTRATION
rj.;!i U.S. FOOD & DRUG - ADMIN ISTRATION HAR 1 0 2017 Anthony Maffia Vice President, Regulatory Affairs Sandoz Inc. 1 00 College Road West Princeton, NJ 08540 Dear Mr. Maffia: Re: Docket No. FDA-2016-P-3356
More informationORANGE BOOK ORANGE BOOK
1 INTRODUCTION: DEFINITION: The official title of the book is Approved Drug Products with Therapeutic Equivalence Evaluations. Orange book is a publication by the Food and Drug Administration which contains
More informationthe May 2010 Draft Guidance on Azelaic Acid, and you request that the FDA take the following actions relating to those comments:
(.t ~stltvic's. ~"~Iy"~ DEPARTMENT OF HEALTH &. HUMAN SERVICES JUN 22 2012 Food and Drug Administration Rockvile MD 20857. David L. Rosen Foley & Lardner LLP 3000 K Street, N.W., Suite 500 Washington,
More informationFlavored Milk; Petition to Amend the Standard of Identity for Milk and 17 Additional Dairy
This document is scheduled to be published in the Federal Register on 02/20/2013 and available online at http://federalregister.gov/a/2013-03835, and on FDsys.gov 4160-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationThree-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the
This document is scheduled to be published in the Federal Register on 05/15/2017 and available online at https://federalregister.gov/d/2017-09754, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationCoventry Health Care of Georgia, Inc.
Coventry Health Care of Georgia, Inc. PRESCRIPTION DRUG RIDER (for High Deductible Health Plans) This Prescription Drug Rider is an attachment to the Coventry Health Care of Georgia, Inc. ( Health Plan
More informationCase 1:09-cv RMB-AMD Document 1 Filed 08/12/09 Page 1 of 6 PageID: 1
Case 1:09-cv-04115-RMB-AMD Document 1 Filed 08/12/09 Page 1 of 6 PageID: 1 John E. Flaherty Jonathan M.H. Short McCARTER & ENGLISH, LLP Four Gateway Center 100 Mulberry Street Newark, New Jersey 07102-4096
More informationNew patients approved for the Novo Nordisk PAP may only be eligible for insulin vials. For a full list of available products, please visit:
The Novo Nordisk Diabetes Patient Assistance Program (PAP) provides medication to qualifying applicants at no charge. If the applicant qualifies under the Novo Nordisk Diabetes PAP guidelines, a 120-day
More informationIndirect Food Additives: Adhesives and Components of Coatings and Paper and Paperboard Components
4 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 175 and 176 [Docket No. 99F-09253 Indirect Food Additives: Adhesives and Components of Coatings and Paper and Paperboard
More informationJAN MbTten Jurs Chief Executive Officer Pronova BioPharma Norge AS P.O. Box 420 NO-1327 Lysaker NORWAY. Docket No.
DEPARTMENT OF HEALTH &. HUMAN SERVICES Food and Drug Administration Rockville MD 20857 JAN 28 2010 MbTten Jurs Chief Executive Officer Pronova BioPharma Norge AS P.O. Box 420 NO-1327 Lysaker NORWAY Re:
More informationjjc Troxyca (Oxycodone Hydrochloride and Naltrexone Hydrochloride) ER capsules (new drug application (NDA) ) TO:
TO: FROM: THROUGH: Troxyca (Oxycodone Hydrochloride and Naltrexone Hydrochloride) ER capsules (new drug application (NDA) 207621) Emily Helms Williams Wi Regulatory Counsel / Office of Regulatory Policy
More informationBUG 8C BEA.$DSLEY, LLP. 919 EIGHTEENTH STREET, N.W. SUITE C300 WASHINGTON, D.C. 2000C3-55ro. October 22, 2009
BUG 8C BEA.$DSLEY, LLP 919 EIGHTEENTH STREET, N.W. SUITE C300 WASHINGTON, D.C. 2000C3-55ro OCT 22?3 '07 W$rrEa's TmmEPjKoxE 202-736-3615 TE-1-Rp$oxE 202-736-3800 FAcsnKn.R 202-736-3608 Dockets Management
More informationJanssen T. October 31, 2016
Docket No. FDA-2011-P-0086-0001/CP Janssen Research & Development, LLC. 1125 Trenton-Harbourton Road, P.O. Box 200 Titusville, NJ 08560 Janssen T October 31, 2016 Division of Dockets Management (HF A 305)
More informationTSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17
TSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17 Division of Pharmaceutical Quality Operations IV 19701 Fairchild, Irvine, CA 92612-2506 Telephone: 949-608-2900 Fax: 949-608-4417 WARNING LETTER VIA SIGNATURE
More informationSection Processing
Section 10000 Processing Table of Contents 10100 Introduction 10200 Participation 10300 Submit Requests in Pounds, Not Cases 10400 Approved Processors 10500 TDA Processing Contracts 10600 Value Pass-Through
More informationOver-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen
Reprinted from FDA s website by EAS Consulting Group, LLC Over-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed
More informationClinical Studies in BE Evaluation of Generic Products. Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs
Clinical Studies in BE Evaluation of Generic Products Brenda S. Gierhart, M.D. Medical Officer, Division of Clinical Review, Office of Generic Drugs 1 Disclaimer The opinions and information in this presentation
More informationMedical gap arrangements - practitioner application
Medical gap arrangements - practitioner application For services provided in a licensed private hospital or day hospital facility (Private Hospital) only. Please complete this form to apply for participation
More informationExhibit 2 RFQ Engagement Letter
Exhibit 2 RFQ 17-25 Engagement Letter The attached includes the 6 page proposed engagement letter to be used by HCC. ENGAGEMENT LETTER Dear: [Lead Counsel/Partner] We are pleased to inform you that your
More informationNational Drug Code Directory
The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or
More informationCase 2:15-cv SRC-CLW Document 9 Filed 02/04/16 Page 1 of 19 PageID: 246
Case 2:15-cv-08180-SRC-CLW Document 9 Filed 02/04/16 Page 1 of 19 PageID: 246 Elvin Esteves Charles H. Chevalier J. Brugh Lower GIBBONS P.C. One Gateway Center Newark, New Jersey 07102 Tel: (973) 596-4500
More informationBruce Wilkinson. Formulary & Benefit (F&B) Copay Summary Recommendation
Bruce Wilkinson Formulary & Benefit (F&B) Copay Summary Recommendation F&B Summary Copay Usage Goal: Use the Summary Copay files in a consistent manner with other F&B file types, specifically formulary
More informationHogan Lovells. December 11, 2013 BY HAND DELIVERY
Hogan Lovells 13 777 BY HAND DELIVERY Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, Maryland 20852 Re: CITIZEN PETITION SUPPLEMENT On behalf of AbbVie Inc. ("AbbVie") 1, the undersigned
More informationDEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f
DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f J Dallas District 4040 North Central Expressway Dallas, Texas 75204-3145 Ref: 2004-DAL-WL-03 WARNING LETTER CERTIFIED MAIL RETURN
More informationNational Drug Code Directory
The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or
More informationNEW PROVIDER ENROLLMENT FOR ADULT SITE
New Jersey Department of Health Vaccines for Children (NJVFC) Program P.O. Box 369 Trenton, NJ 08625-0369 Phone: (609) 826-4862 Fax: (609) 826-4868 INSTRUCTIONS: Email completed New Provider Enrollment
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry Bar Code Label Requirements Questions and Answers (Question 12 Update) DRAFT GUIDANCE This guidance document is for comment purposes only. Submit comments
More informationGENERAL INFORMATION AND INSTRUCTIONS
NON-PARTICIPATING MANUFACTURER CERTIFICATION FOR LISTING ON OREGON DIRECTORY GENERAL INFORMATION AND INSTRUCTIONS Who is required to file this Certification? Any tobacco product manufacturer who is a non-participating
More informationOpioid Policy Steering Committee: Prescribing Intervention--Exploring a Strategy for
This document is scheduled to be published in the Federal Register on 12/13/2017 and available online at https://federalregister.gov/d/2017-26785, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationSoma)con PHARMACEUTICALS
Soma)con PHARMACEUTICALS 5357 11 OCT 20 A10 AO Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852
More informationClinical Endpoint Bioequivalence Study Review in ANDA Submissions. Ying Fan, Ph.D.
Clinical Endpoint Bioequivalence Study Review in ANDA Submissions Ying Fan, Ph.D. 1 Disclaimer This presentation constitutes an informal communication that represents the best judgment of the speaker at
More informationUNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT
UNITED STATES COURT OF APPEALS FOR THE FEDERAL CIRCUIT Date of docketing: December 1, 2017 NOTICE OF DOCKETING 18-1247 - Amarin Pharma, Inc. v. ITC Appeal from: U.S. International Trade Commission Investigation
More informationIN THE UNITED STATES PATENT AND TRADEMARK OFFICE
In re Patent Application of: Neil P. DESAI et al. Docket No.: 638772000109 (PATENT) IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Application No.: 11/520,479 Filed: September 12, 2006 For: NOVEL FORMULATIONS
More informationRe: National Bioengineered Food Disclosure Standard; Proposed Rule; Request for Comments, 83 Fed. Reg (May 4, 2018), Docket No.
VIA ELECTRONIC SUBMISSION July 3, 2018 Dockets Management Staff (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: National Bioengineered Food Disclosure Standard;
More informationGuidance for Industry
Guidance for Industry Dosage Delivery Devices for OTC Liquid Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationSUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is proposing to
This document is scheduled to be published in the Federal Register on 10/26/2016 and available online at https://federalregister.gov/d/2016-25850, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationAPPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS
APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 34 th EDITION THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT. U.S. DEPARTMENT
More informationOFFICE OF PHARMACEUTICAL SCIENCES. COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS
MANUAL OF POLICIES AND PROCEDURES CENTER FOR DRUG EVALUATION AND RESEARCH MAPP 5015.3 OFFICE OF PHARMACEUTICAL SCIENCES COVER FORM FOR THE TECHNICAL REVIEW OF DRUG MASTER FILES (DMFs) CONTENTS PURPOSE
More informationFood Labeling: Revision of the Nutrition and Supplement Facts Labels and Serving Sizes of
This document is scheduled to be published in the Federal Register on 10/02/2017 and available online at https://federalregister.gov/d/2017-21019, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationMartin Shimer Deputy Director, Division of Legal and Regulatory Support Office of Generic Drug Policy
M E M O R A N D U M DEPARTMENT OF HEALTH AND HUMAN SERVICES PUBLIC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION AND RESEARCH DATE: November 9, 2017 FROM: Martin Shimer Deputy
More informationSUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is amending its
This document is scheduled to be published in the Federal Register on 10/26/2016 and available online at https://federalregister.gov/d/2016-25851, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationNOV
DEPARTMENT OF HEALTH &, HUMAN SERVICES ------------------------------------------ NOV 17 2010 Food and Drug Administration Rockville M D 20857 Mark S. Aikman, Pharm.D. Vice President, Regulatory Affairs
More informationOrganisational reporting of completion fees apply
Self reporting of completion free service Proof of completion of all courses is provided to all learners in the form of a printable and emailable Certificate of Completion. Learners can use these certificates
More informationListing of Color Additives Exempt from Certification; Synthetic Iron Oxide
This document is scheduled to be published in the Federal Register on 03/20/2015 and available online at http://federalregister.gov/a/2015-06418, and on FDsys.gov DEPARTMENT OF HEALTH AND HUMAN SERVICES
More informationAgency Information Collection Activities; Submission for Office of Management and
This document is scheduled to be published in the Federal Register on 02/19/2019 and available online at https://federalregister.gov/d/2019-02596, and on govinfo.gov 4164-01-P DEPARTMENT OF HEALTH AND
More informationGeneric Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;
4160-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 15 [Docket No. FDA-2013-N-0402] Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public
More informationRULES OF TENNESSEE DEPARTMENT OF AGRICULTURE DIVISION OF MARKETING CHAPTER COMMERCIAL FERTILIZER TABLE OF CONTENTS
RULES OF TENNESSEE DEPARTMENT OF AGRICULTURE DIVISION OF MARKETING CHAPTER 0080-05-10 COMMERCIAL FERTILIZER TABLE OF CONTENTS 0080-05-10-.01 Definitions and Terms 0080-05-10-.07 Labeling of Soil Conditioners
More informatione-cigarette Regulation
e-cigarette Regulation The Act prohibits the sale of electronic smoking devices and alternative nicotine products to minors, and requires child-resistant packaging for liquid nicotine containers. The Act
More informationIN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD CELLTRION, INC. Petitioner
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD CELLTRION, INC. Petitioner v. GENENTECH, INC. AND BIOGEN IDEC, INC. Patent Owners U.S. Patent No. 7,820,161 B1
More informationMEMBER SHARE A Pastoral Medical Association - Private Membership Program MEMBER SHARE AGREEMENT (MSA)
MSA P MEMBER SHARE A Pastoral Medical Association - Private Membership Program MEMBER SHARE AGREEMENT (MSA) I, the undersigned applicant for the value, benefits and mutual promises herein, do hereby apply
More informationMYCAMINE National Drug Code Directory
0469-3250-10 MYCAMINE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs
More informationNDA NDA APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 022200 NDA APPROVAL Amylin Pharmaceuticals, Inc. Orville Kolterman, M.D. Sr. Vice President, Research & Development
More informationDear Applicant for Sober Living Environment Registration,
Dear Applicant for Sober Living Environment Registration, Thank you for your interest in Sober Living Registration. The California Consortium of Addiction Programs and Professionals, (CCAPP) endorses the
More informationClass II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA
Class II Special Controls Guidance Document: Intraoral Devices for Snoring and/or Obstructive Sleep Apnea; Guidance for Industry and FDA Document issued on: November 12, 2002 This document supersedes the
More informationMark M. Yacura. Partner
Mark M. Yacura Partner Mark M. Yacura focuses his practice primarily on FDA legal and regulatory matters. He has practiced in this area for more than 30 years. He represents his clients before administrative
More informationDEXAMETHASONE SODIUM PHOSPHATE National Drug Code Directory
0641-6146-25 DEXAMETHASONE SODIUM PHOSPHATE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current
More informationECOCERT CANADA LABELLING GUIDE. For Canadian Certified Organic Products. Version3
ECOCERT CANADA LABELLING GUIDE For Canadian Certified Organic Products Version3 2014 TABLE OF CONTENTS Validation of label design........3 Use of the Ecocert Trademark....4 Changes to labels.... 4 Prerequisites
More informationLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory
0409-3178-03 LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA)
More informationKETAMINE HYDROCHLORIDE National Drug Code Directory
42023-138-10 KETAMINE HYDROCHLORIDE The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured,
More informationyour submissions dated October 12, No.vember 9 and 1, and April 7,2008.
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service (.,... t. ~J'O ~~ Food and Drug Administration """'~4~""RVIC'S' ''r Rockvile, MD 20857 STN: BL 125118/045 Bristól~Myers Squibb Company P.O. Box
More informationINRANGE SYSTEMS. Citizen Petition
INRANGE SYSTEMS I~ I~ ;111Q I~ I tim@ II lifi11 Ill~ 1!1 II: I@ ;I@~ lij December 26, 2014 ZOI5 JA. -5 P 1: 15 Division of Dockets Management Food and Drug Administration 5630 Fishers Lane, Room 1061 (HFA-305)
More informationResidual Solvents: FDA/ Regulatory Perspective
Rosa Motta Compliance Officer Residual Solvents: FDA/ Regulatory Perspective PDA/USP Residual Solvents Conference January 18-19, 2007 1 Outline Laws and regulations governing the compliance requirements
More informationANDA Labeling Question Based Review September 11, 2013 GPhA/FDA ANDA Labeling Workshop/USP User Forum
ANDA Labeling Question Based Review September 11, 2013 GPhA/FDA ANDA Labeling Workshop/USP User Forum Sarah Park, PharmD Jeanne Skanchy, RPh. Labeling Reviewers Office of Generic Drugs/Division of Labeling
More informationFacilitate physician access to compounded drugs for office-use from 503A compounding pharmacies for patients with emergent conditions;
By Electronic Delivery Scott Gottlieb, MD Commissioner Food and Drug Administration Attn: Division of Dockets Management (HFA-305) 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA-2017-N-5093 for
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Home Inspections, Compliance, Enforcement, and Criminal Investigations Enforcement Actions Warning Letters Inspections, Compliance, Enforcement, and Criminal Investigations Burzynski Research Institute
More informationCold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for. Over-the-Counter Human Use; Amendment of Monograph for OTC Nasal
1 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 341 [Docket No. 1976N 0052N] (formerly 76N 052N) RIN 0910 AF34 Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic
More informationSUMMARY: The Food and Drug Administration (FDA or we) is amending the color additive
This document is scheduled to be published in the Federal Register on 08/21/2015 and available online at http://federalregister.gov/a/2015-20676, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationPHENYTOIN SODIUM National Drug Code Directory
57664-808-88 PHENYTOIN SODIUM National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of
More informationCENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER: Orig1s000 APPROVAL LETTER
CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 202107Orig1s000 APPROVAL LETTER DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 202107 NDA APPROVAL
More informationLOREAL USA. February 6, Theresa Michelle, M.D.
Theresa Michelle, M.D. LOREAL ~OREAL USA PRODUCTS, Inc. - Clark, NJ 07066 2) Chemical structure: 1) Product name: Drometrizole trisiloxane The following information is being provided for the purposes of
More informationThe Food and Drug Administration's Approach to Evaluating Nicotine Replacement Therapies;
This document is scheduled to be published in the Federal Register on 11/30/2017 and available online at https://federalregister.gov/d/2017-25671, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationNaloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program
Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program Andrea Leonard-Segal, M.D., M.S. Director, Division of Nonprescription Clinical Evaluation 1 Contents
More informationEMERGENCY FOOD ASSISTANCE PROGRAM CLUSTER
APRIL 2015 CLUSTER 10.568 10.569 State Project/Program: (ADMINISTRATIVE COSTS) (USDA FOODS) U.S. Department of Agriculture Federal Authorization: State Authorization: 7 CFR 251, Public Law 98-8, 7 USC
More informationNational Drug Code Directory
The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or
More informationSeasonal Flu Vaccine Offers 2015/16
Seasonal Flu Vaccine Offers 2015/16 The LMC Buying Groups Federation has concluded negotiations with flu vaccine companies for the 2015/16 season and we can now announce that our 1 st preferred supplier
More informationCase 1:17-cv UNA Document 1 Filed 02/14/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE
Case 1:17-cv-00159-UNA Document 1 Filed 02/14/17 Page 1 of 10 PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE PFIZER INC., PF PRISM C.V., and C.P. PHARMACEUTICALS INTERNATIONAL
More informationBelow is the indication and summary of the most serious and most common risks associated with the use of Naftin Cream, 2%. 2
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Silver Spring, MD 20993 TRANSMITTED BY FACSIMILE Misty M. D Ottavio, Senior Manager Regulatory Affairs 4215 Tudor
More informationInformed Consent for MINDFULNESS BASED Cognitive Therapy
Informed Consent for MINDFULNESS BASED Cognitive Therapy The state expects that you will be informed of all possible contingencies that might arise in the course of short - and long-term therapy. Please
More informationDepartment of Legislative Services Maryland General Assembly 2007 Session. FISCAL AND POLICY NOTE Revised
House Bill 785 Economic Matters Department of Legislative Services Maryland General Assembly 2007 Session FISCAL AND POLICY NOTE Revised (Delegate Malone, et al.) HB 785 Finance Cigarette Fire Safety Performance
More information